

Bjarne R Bartlett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1714836/publications.pdf>

Version: 2024-02-01

23
papers

17,377
citations

777949

13
h-index

1051228

16
g-index

24
all docs

24
docs citations

24
times ranked

26289
citing authors

#	ARTICLE	IF	CITATIONS
1	Digital technology helps remove gender bias in academia. <i>Scientometrics</i> , 2021, 126, 4073-4081.	1.6	11
2	The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF- β 2 as a Companion Target for Checkpoint Blockade Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 754507.	1.8	3
3	Development of a RNA-Seq based prognostic signature for colon cancer. <i>International Journal of Computational Biology and Drug Design</i> , 2020, 13, 488.	0.3	0
4	Development of a RNA-Seq based prognostic signature for colon cancer. <i>International Journal of Computational Biology and Drug Design</i> , 2020, 13, 488.	0.3	0
5	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1574-1579.	1.6	33
6	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 5250-5259.	3.2	46
7	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	6.0	395
8	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
9	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 7024-7034.	3.2	104
10	Abstract 4058: The miRNA expression profile of inflammatory tumors reveals a unique immune cell profile and potential companion targets for checkpoint blockade immunotherapy. , 2019, , .		0
11	Abstract 4058: The miRNA expression profile of inflammatory tumors reveals a unique immune cell profile and potential companion targets for checkpoint blockade immunotherapy. , 2019, , .		0
12	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
13	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2017, 23, 2471-2477.	3.2	154
14	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 103-103.	0.8	50
15	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3003-3003.	0.8	24
16	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 195-195.	0.8	39
17	Abstract 3957: Optimized plasma collection procedures for liquid biopsy analyses in cancer. , 2016, , .		0
18	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696

#	ARTICLE	IF	CITATIONS
19	Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer.. Journal of Clinical Oncology, 2015, 33, 11025-11025.	0.8	2
20	PD-1 blockade in tumors with mismatch repair deficiency.. Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	0.8	31
21	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	5.8	3,665
22	DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES. Neuro-Oncology, 2014, 16, iii7-iii7.	0.6	50
23	Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies. , 2014, , .		83